Test ID: GABCC
GABA-B-Receptor Antibody by CBA, Spinal Fluid
Secondary ID 
A test code used for billing and in test definitions created prior to November 2011
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Useful For Suggests clinical disorders or settings where the test may be helpful
Evaluating new onset encephalopathy encompassing 1 or more of the following: confusional states, psychosis, delirium, memory loss, hallucinations, seizures, dyssomnias, coma, dysautonomias, or hypoventilation
The following accompaniments should prompt suspicion for autoimmune encephalopathy:
-Headache
-Autoimmune stigmata (personal or family history, or signs of diabetes mellitus, thyroid disorder, vitiligo, poliosis [premature graying], myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus)
-History of cancer
-Smoking history (20+ pack years) or other cancer risk factors
-Inflammatory cerebrospinal fluid or isolated protein elevation
-Neuroimaging signs suggesting inflammation
Evaluating limbic encephalitis
Directing a focused search for cancer
Investigating encephalopathy appearing in the course or wake of cancer therapy, and not explainable by metastasis or drug effect
Method Name A short description of the method used to perform the test
Cell-binding assay (CBA) detects IgG specific for Gamma-Amino Butyric acid-type B receptor (GABA-B-R) by indirect immunofluorescence (IFA)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Aliases Lists additional common names for a test, as an aid in searching
GABA-B Receptor Ab
Gamma-Aminobutyric Acid Receptor Ab
External
link
PDF
document
Excel
document
Word
document